Month: November 2025

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

11/17/2025

Excerpt from the Press Release: BOSTON and SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, Pte. Ltd, a biotechnology company developing next-generation T…

MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome

11/14/2025

First Gene Therapy Trial for Angelman Syndrome -Orphan Drug Designation Granted for MVX-220 Excerpt from the Press Release: MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2…

Montai Therapeutics Presents Preclinical Data on NRF2 Agonist in Ulcerative Colitis at ACAAI Annual Meeting

11/13/2025

Program derived from Montai’s Anthromolecule chemistry demonstrates potent selectivity and efficacy against a triad of key mechanisms implicated in UC Company’s first development candidate to advance to IND-enabling studies Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Montai Therapeutics, a company harnessing AI to decode untapped, diverse chemistry to develop breakthrough medicines for chronic disease, will…

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

11/12/2025

Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board’s Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment Strategies Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies…

Avobis Bio Presents Positive Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial at a Plenary Session of the American College of Gastroenterology’s Annual Scientific Meeting

11/11/2025

The Implantable Cell Therapy AVB-114 Demonstrated Favorable Safety and Effectiveness in the Phase II Trial for Crohn’s Perianal Fistulas – Excerpt from the Press Release: NEWARK, Del., Oct. 29, 2025 /PRNewswire/ — Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced that the STOMP2 primary analysis results were revealed today at a…

Sonoma Biotherapeutics Announces Positive Interim Safety and Efficacy Data from Phase 1 REGULATE-RA Study of SBT-77-7101 in Refractory Rheumatoid Arthritis

11/10/2025

Favorable early safety profile with preliminary clinical and mechanistic evidence of therapeutic activity in refractory rheumatoid arthritis Data to be presented in a late-breaking oral presentation today 8:00 a.m. CT at the 2025 American College of Rheumatology (ACR) Convergence Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & SEATTLE–(BUSINESS WIRE)–Sonoma Biotherapeutics, Inc., a clinical-stage…

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

11/07/2025

Excerpt from the Press Release: WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF. The topline data showed that a single intravenous dose…

Toragen, Inc., Receives Grant to Conduct Studies to Explore Application of TGN-S15 for Premalignant Lesions at Earliest Stages

11/06/2025

The next 6 months of scientific studies to investigate the utility in early stage, premalignant lesions of Toragen’s first-in-class small molecule, oral drug candidate TGN-S15 is funded by the Gates Foundation. Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., an oncology biopharmaceutical company focused on the development of TGN-S15, their oral, small molecule drug…

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

11/05/2025

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in…

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

11/04/2025

CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial…